ETFs
I
IMCR
Immunocore Holdings Plc
32.09
+2.25+7.54%Opening13:02 10/20 EDT
OPEN/PREV CLOSE30.11/29.84
TODAY RANGE30.11-32.10
VOL318.53K
MARKET CAP1.65B
52 WEEK RANGE27.50-40.71
AVG VOL (3M)428.51K
% TURNOVER0.62%
TURNOVER--
P/E (TTM)-87.0828
% RANGE6.67%
EPS(TTM)-0.3685
P/E(FORWARD)-7.1073
P/B3.935
BVPS8.15
DIVIDEND--
P/S4.066
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.64B
SHARES OUTSTANDING51.50M
NEXT EARNINGS11/04-11/09
FREE FLOAT50.98M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
Immunocore Holdings (IMCR) Enters Type 1 Diabetes Following Trial Debut And An Undervalued View
Simply Wall St·4d ago
Should First Patient Dosed Require Action From Immunocore Stock Investors?
TipRanks·5d ago
Immunocore doses first patient in IMC-S118AI trial
Benzinga·10/05 13:05
Immunocore Hldgs Q2 2026 Earnings Call Transcript
Seeking Alpha·09/29 13:20
Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial
Simply Wall St·09/21 20:23
Is Full Trial Enrollment Altering The Investment Case For Immunocore Stock (IMCR)?
TipRanks·09/14 11:50
Immunocore Completes Enrollment in Phase 3 Melanoma Trial
TipRanks·09/14 11:20
Immunocore achieves target patient enrollment in TEBE-AM clinical trial
Dow Jones·08/21 19:17
Immunocore Holdings Price Target Announced at $50.00/Share by JP Morgan
TipRanks·08/21 10:30
Immunocore reinstated with an Overweight at JPMorgan
Simply Wall St·08/17 21:25
Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?
Simply Wall St·08/14 06:35
How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback
Same Industry
Name/Symbol
Change%
Price